- Home
- NAMS
as 09-18-2025 4:00pm EST
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.
| Founded: | 2019 | Country: | Netherlands |
| Employees: | N/A | City: | NARRDEN |
| Market Cap: | 2.7B | IPO Year: | N/A |
| Target Price: | $41.40 | AVG Volume (30 days): | 984.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.06 - $27.35 | Next Earning Date: | 11-05-2025 |
| Revenue: | $64,006,000 | Revenue Growth: | 762.15% |
| Revenue Growth (this year): | -33.32% | Revenue Growth (next year): | 1.67% |
Latest NewAmsterdam Pharma Company N.V. News
NAMS Breaking Stock News: Dive into NAMS Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
Newamsterdam Pharma Insider Sold Shares Worth $3,874,017, According to a Recent SEC Filing
MT Newswires
13 days ago
Newamsterdam Pharma Insider Sold Shares Worth $453,452, According to a Recent SEC Filing
Simply Wall St.
3 months ago
Analysts Have Just Cut Their NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Revenue Estimates By 14%
GlobeNewswire
3 months ago
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
GlobeNewswire
3 months ago
NewAmsterdam Pharma to Host R&D Day on June 11, 2025
GlobeNewswire
4 months ago
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
GlobeNewswire
4 months ago
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
Simply Wall St.
4 months ago
NewAmsterdam Pharma First Quarter 2025 Earnings: US$0.34 loss per share (vs US$1.06 loss in 1Q 2024)
Compare NAMS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NAMS NewAmsterdam Pharma Company N.V. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.